Cerluten 20mg
An oral animal-derived central nervous system peptide complex investigated in bioregulator models for neural integrity and cognitive health.
Mechanism
Postulated to act via tissue-specific organotropic signaling where low-molecular-weight brain-derived peptides modulate gene expression, support neuronal metabolism, and mitigate cellular excitotoxicity.
Dosing
Standard investigational protocols typically document an initial administration of 20 mg (one capsule) daily.
Reconstitution
Cerluten is an encapsulated solid intended for oral research and requires no reconstitution with bacteriostatic water.
Storage
Store sealed at controlled room temperature in a dry location shielded from heat and direct light.
Mix & measure Cerluten 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Cerluten 20mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: —
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Initiation (Days 1–10) | 20 mg (1 capsule) daily | N/A (Oral) |
| Standard Course (Days 11–30) | 20–40 mg (1–2 capsules) daily | N/A (Oral) |
| Maintenance Pulse | Repeat 10–30 day course 2–3 times/year | N/A (Oral) |
Reconstitution Steps
- 1
Verify the integrity of the packaging and confirm the labeled milligram strength per capsule.
- 2
Bypass liquid reconstitution procedures, as this preparation is provided as a pre-measured solid oral capsule.
- 3
Ensure standard oral delivery equipment (such as clean laboratory water for swallowing) is prepared.
- 4
Administer the capsule intact without crushing, opening, or dissolving the outer shell.
- 5
Reseal the original container immediately to prevent exposure to ambient moisture or degradation.
Supplies Needed
Peptide Vial
Encapsulated oral bioregulator supply containing 20 mg of brain tissue peptide complex
Insulin Syringes (U-100)
Not applicable for this oral formulation
Bacteriostatic Water
Not applicable for solid capsule administration
Alcohol Swabs
Not required for enteral laboratory administration
Why researchers study it
Brain & cognitive health models
Neuronal recovery and ischemic cascades
Tissue-specific bioregulator peptide mechanisms
Enteral peptide absorption and CNS signaling
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Cerluten (designated Cytomax A-5) represents a proprietary biological extract derived from animal central nervous system tissue, specifically formulated as an oral peptide bioregulator. Developed within the conceptual framework of Russian organotropic peptide research, it is investigated for its potential role in modulating cellular homeostasis, protein synthesis, and metabolic resilience within neuronal tissue. While marketed and utilized internationally as a dietary supplement or parapharmaceutical, scientific investigations into natural brain bioregulators frequently intersect with findings from defined pharmaceutical counterparts, such as Cortexin and the synthetic peptide Cortagen. Researchers frequently assess Cerluten to explore whether short-chain, tissue-specific peptide mixtures exert comparable cellular-signaling or neuroprotective influences when administered via enteral pathways. Because Cerluten is supplied exclusively as a solid oral preparation, standard peptide laboratory techniques involving reconstitution, liquid measurement, and parenteral injection do not apply. The literature primarily documents its use across structured multi-week pulses rather than persistent chronic regimens.
References
- 1.Khavinson, Neuroendocrinology Letters, 2002 — Peptides and Ageing
- 2.Fedin et al., Zh Nevrol Psikhiatr im S.S. Korsakova, 2021 — Multimodal therapeutic strategies in cerebrovascular disease
- 3.Shavlovskaya, Zh Nevrol Psikhiatr im S.S. Korsakova, 2016 — Clinical efficacy of neuropeptides in cerebrovascular pathology
- 4.Khavinson et al., Advances in Gerontology, 2013 — Peptide bioregulators: a new class of geroprotectors (clinical studies results)
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allAmycretin 5mg
Dual GLP-1 and amylin receptor agonist investigated for potent satiety induction and body weight regulation.
View ProtocolGLOW (GHK-Cu + TB-500 + BPC-157)
A 70 mg multi-peptide research formulation combining GHK-Cu, TB-500, and BPC-157 in a fixed 5:1:1 ratio for tissue repair investigations.
View ProtocolChonluten 20mg
Chonluten is a synthetic tripeptide bioregulator investigated for its tissue-specific role in modulating bronchopulmonary gene expression.
View Protocol